Detalhe da pesquisa
1.
First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia.
N Engl J Med
; 388(19): 1739-1754, 2023 May 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37163621
2.
Acalabrutinib, venetoclax and obinutuzumab in relapsed CLL: Final efficacy and ctDNA analysis of the CLL2-BAAG trial.
Blood
; 2024 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38620072
3.
Reassessing the Chronic Lymphocytic Leukemia International Prognostic Index in the era of targeted therapies.
Blood
; 2024 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38620092
4.
T-bet suppresses proliferation of malignant B cells in chronic lymphocytic leukemia.
Blood
; 2024 Apr 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38684038
5.
Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mut.
Blood
; 142(11): 961-972, 2023 09 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-37363867
6.
High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations.
Blood
; 142(5): 446-459, 2023 08 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-37172204
7.
First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol
; 25(6): 744-759, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38821083
8.
Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia.
Blood
; 139(9): 1318-1329, 2022 03 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35108374
9.
Fludarabine, cyclophosphamide, and rituximab as first-line treatment in patients with chronic lymphocytic leukemia: A long-term analysis of the German CLL Study Group (GCLLSG) registry.
Eur J Haematol
; 2024 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38693677
10.
A practical guide to pulsed laser deposition.
Chem Soc Rev
; 52(7): 2294-2321, 2023 Apr 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36916771
11.
Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutations.
Blood
; 138(19): 1805-1816, 2021 11 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34086865
12.
Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL.
Blood
; 137(10): 1365-1376, 2021 03 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32992344
13.
Strain engineering of the charge and spin-orbital interactions in Sr2IrO4.
Proc Natl Acad Sci U S A
; 117(40): 24764-24770, 2020 Oct 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32958669
14.
IGLV3-21*01 is an inherited risk factor for CLL through the acquisition of a single-point mutation enabling autonomous BCR signaling.
Proc Natl Acad Sci U S A
; 117(8): 4320-4327, 2020 02 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-32047037
15.
Modeling the B-cell receptor signaling on single cell level reveals a stable network circuit topology between nonmalignant B cells and chronic lymphocytic leukemia cells and between untreated cells and cells treated with kinase inhibitors.
Int J Cancer
; 151(5): 783-796, 2022 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35527719
16.
Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax.
Blood
; 135(26): 2402-2412, 2020 06 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-32206772
17.
Clonal evolution in chronic lymphocytic leukemia is scant in relapsed but accelerated in refractory cases after chemo(immune) therapy.
Haematologica
; 107(3): 604-614, 2022 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33691380
18.
Integrative prognostic models predict long-term survival after immunochemotherapy in chronic lymphocytic leukemia patients.
Haematologica
; 107(3): 615-624, 2022 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33730841
19.
IGF1R as druggable target mediating PI3K-δ inhibitor resistance in a murine model of chronic lymphocytic leukemia.
Blood
; 134(6): 534-547, 2019 08 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31010847
20.
Reconstruction of rearranged T-cell receptor loci by whole genome and transcriptome sequencing gives insights into the initial steps of T-cell prolymphocytic leukemia.
Genes Chromosomes Cancer
; 59(4): 261-267, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31677197